Across TCGA pan-cancer cohorts, MPIG6B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MPIG6B data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher MPIG6B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MPIG6B expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

SCLC, HNSC, and BLCA are the cancer types where MPIG6B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.192	0.713	.001	33	view →
HNSC	OS	Median	All	0.176	0.685	.024	30	view →
BLCA	DFS	Median	All	0.086	0.628	<.001	27	view →
LUSC	OS	Median	All	0.011	0.819	<.001	18	view →
SKCM	DFS	Median	III,IV	1.000	0.470	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: MPIG6B tumor-vs-normal RNA expression · all MPIG6B data types